Longitudinal DAT changes measured with [18F]FE-PE2I PET in patients with Parkinson?s disease; a validation study

Background: Dopamine transporter (DAT) PET provides higher resolution than DAT SPECT and opportunity for integrated imaging with MRI. The radioligand [18F]FE-PE2I is highly selective for the DAT, and PET measure-ments with this radioligand have good reliability and repeatability in patients with non-advanced Parkinson's disease.Objectives: To validate [18F]FE-PE2I PET as measurement tool of longitudinal DAT changes in patients with Parkinson's disease.Methods: Thirty-seven subjects with Parkinson's disease (Hoehn and Yahr stage < 3) were included in a longi-tudinal PET study with [18F]FE-PE2I. DAT availability (BPND) in the caudate nucleus, putamen, sensorimotor striatum, and substantia nigra, was estimated with parametric imaging using Logan graphical analysis and cerebellum as reference region. For comparison with DAT-SPECT literature, sample size calculations for disease intervention studies were made.Results: Baseline and follow-up PET data (interval: 2.3 +/- 0.5 years) were available for 25 patients (9 females, 16 males). Median age was 64.7 years (range 46-76); symptom duration: 3 years (0.25-14); Hoehn and Yahr stage (H&Y): 1 (1-2). Annualized DAT decline and effect size were:-8.5 +/- 6.6 % and 1.08 for caudate nucleus;-7.1 +/- 6.1 % and 1.02 for putamen;-8.3 +/- 8.5 % and 0.99 for sensorimotor striatum;-0.11 +/- 9.3 % and 0.11 for substantia nigra. The estimated minimum sample size needed for a treatment trial using [18F]FE-PE2I PET as imaging marker is 2-3 times lower than is reported in literature on [123I]FP-CIT SPECT.Conclusions: Longitudinal [18F]FE-PE2I PET measurements in non-advanced PD demonstrate a striatal DAT decline consistent with previous SPECT and PET studies. No obvious changes of DAT availability were observed in the substantia nigra, indicating perhaps slower progression or compensatory changes. The effect sizes were numerically larger than reported in the literature for other DAT radioligands, suggesting that [18F]FE-PE2I might detect smaller DAT changes, and can be well used as progression marker in clinical trials.

Automated summary

This study validates the efficacy of [18F]FE-PE2I PET as a measurement tool for longitudinal DAT changes in patients with Parkinson's disease. The results show a significant decline in DAT availability measured by [18F]FE-PE2I PET in early-stage Parkinson's disease patients, with larger effect sizes compared to previous SPECT and PET studies. This suggests that [18F]FE-PE2I can be used as a progression marker in clinical trials.